Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Bupivacaine Injection for Management of Lagophthalmos Due to Long-Standing Idiopathic Facial Nerve Palsy Publisher Pubmed



Rajabi MT1 ; Shadravan M1 ; Mazloumi M1 ; Tabatabaie SZ1 ; Hosseini SS1 ; Rajabi MB1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, Farabi Eye Hospital, Department of Ophtalmology, Tehran University of Medical Sciences, Qazvin Square, Tehran, 1336616351, Iran

Source: Ophthalmic Plastic and Reconstructive Surgery Published:2015


Abstract

Purpose: To report the results of bupivacaine injection into the orbicularis oculi muscle to treat lagophthalmos in patients with long-standing Bell palsy. Methods: In this prospective interventional case series, bupivacaine, 5 ml of a 0.750% solution, was injected into the preseptal and pretarsal area of the orbicularis oculi in each of 10 patients with idiopathic peripheral facial nerve palsy. The measures of vertical eyelid apertures during open and closed eyes were made before the procedure and 1, 3, and 6 months after injection. Results: A total of 10 eyes including 2 men and 8 women with an average age of 43 years (26-64 years) were studied. The mean amount of lagophthalmos before injection and after 6 months of follow up were 3.9 mm and 2.3 mm, respectively (p = 0.01)). The mean amount of corneal exposure before injection and after 6 months of follow up was 1.05 mm and 0.25 mm, respectively (p < 0.01). The mean scleral show in open eyes before injection and after 6 months of follow up were 1.20 mm and 0.75 mm, respectively (p = 0.08). The mean scleral show in closed eyes before injection and after 6 months of follow up were 1.95 mm and 1.15 mm, respectively (p = 0.01). All the patients reported significant decrease in epiphora. Conclusion: Bupivacaine injection in the paretic orbicularis oculi muscle improves eyelid closure and lagophthalmos and epiphora. © 2015 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.